Cytosorbents Corporation (CTSO)
Cytosorbents Statistics
Share Statistics
Cytosorbents has 62.61M shares outstanding. The number of shares has increased by 0.96% in one year.
| Shares Outstanding | 62.61M |
| Shares Change (YoY) | 0.96% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 28.15% |
| Shares Floating | 51.92M |
| Failed to Deliver (FTD) Shares | 90 |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
The latest short interest is 1.62M, so 2.6% of the outstanding shares have been sold short.
| Short Interest | 1.62M |
| Short % of Shares Out | 2.6% |
| Short % of Float | 2.82% |
| Short Ratio (days to cover) | 21.27 |
Valuation Ratios
The PE ratio is -2.39 and the forward PE ratio is -7.14. Cytosorbents's PEG ratio is 0.06.
| PE Ratio | -2.39 |
| Forward PE | -7.14 |
| PS Ratio | 1.39 |
| Forward PS | 0.5 |
| PB Ratio | 4.46 |
| P/FCF Ratio | -3.37 |
| PEG Ratio | 0.06 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Cytosorbents.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.2, with a Debt / Equity ratio of 2.42.
| Current Ratio | 2.2 |
| Quick Ratio | 1.92 |
| Debt / Equity | 2.42 |
| Debt / EBITDA | -1.4 |
| Debt / FCF | -1.83 |
| Interest Coverage | -12 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $238.89K |
| Profits Per Employee | $-139.05K |
| Employee Count | 149 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 3.83 |
Taxes
| Income Tax | -1.69M |
| Effective Tax Rate | 7.55% |
Stock Price Statistics
The stock price has increased by 18.95% in the last 52 weeks. The beta is 1.17, so Cytosorbents's price volatility has been higher than the market average.
| Beta | 1.17 |
| 52-Week Price Change | 18.95% |
| 50-Day Moving Average | 1.05 |
| 200-Day Moving Average | 1.05 |
| Relative Strength Index (RSI) | 45.97 |
| Average Volume (20 Days) | 102.19K |
Income Statement
In the last 12 months, Cytosorbents had revenue of 35.59M and earned -20.72M in profits. Earnings per share was -0.38.
| Revenue | 35.59M |
| Gross Profit | 25.13M |
| Operating Income | -16.79M |
| Net Income | -20.72M |
| EBITDA | -19.26M |
| EBIT | -21.01M |
| Earnings Per Share (EPS) | -0.38 |
Balance Sheet
The company has 3.28M in cash and 26.89M in debt, giving a net cash position of -23.61M.
| Cash & Cash Equivalents | 3.28M |
| Total Debt | 26.89M |
| Net Cash | -23.61M |
| Retained Earnings | -304.01M |
| Total Assets | 47.37M |
| Working Capital | 11.78M |
Cash Flow
In the last 12 months, operating cash flow was -14.43M and capital expenditures -284.34K, giving a free cash flow of -14.71M.
| Operating Cash Flow | -14.43M |
| Capital Expenditures | -284.34K |
| Free Cash Flow | -14.71M |
| FCF Per Share | -0.27 |
Margins
Gross margin is 70.59%, with operating and profit margins of -47.16% and -58.21%.
| Gross Margin | 70.59% |
| Operating Margin | -47.16% |
| Pretax Margin | -62.96% |
| Profit Margin | -58.21% |
| EBITDA Margin | -54.11% |
| EBIT Margin | -47.16% |
| FCF Margin | -41.33% |
Dividends & Yields
CTSO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CTSO is $6.5, which is 550% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.5 |
| Price Target Difference | 550% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Dec 5, 2014. It was a backward split with a ratio of 1:25.
| Last Split Date | Dec 5, 2014 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -8.27 |
| Piotroski F-Score | 4 |